

Electronic Acknowledgement Receipt

EFS ID:	10130775
Application Number:	10576981
International Application Number:	
Confirmation Number:	8112
Title of Invention:	Method Of Therapy
First Named Inventor/Applicant Name:	Martin Leonard Ashdown
Customer Number:	22442
Filer:	Robert D. Traver
Filer Authorized By:	
Attorney Docket Number:	5517-18
Receipt Date:	19-MAY-2011
Filing Date:	02-MAR-2007
Time Stamp:	19:03:56
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$1270
RAM confirmation Number	5226
Deposit Account	191970
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part /.zip	Pages (if appl.)
1		Response_to_Final_OA.pdf	763377 38a670d74e1bb0c4f260c365690bd97c781 c9203	yes	30
Multipart Description/PDF files in .zip description					
Document Description		Start		End	
Amendment/Argument after Notice of Appeal		1		1	
Claims		2		6	
Applicant Arguments/Remarks Made in an Amendment		7		30	

Warnings:

Information:

2	Affidavit/Dec/Exhibit after Notice of Appeal	Dec_of_Coventry.pdf	282276 b75cd44eb205325a651369dac9756cc89d0 9cd9d	no	6
---	--	---------------------	--	----	---

Warnings:

Information:

3	Request for Continued Examination (RCE)	RCE.pdf	81960 ba2989d30474c114dfa28ec9164d420d0f9 7927d	no	1
---	---	---------	---	----	---

Warnings:

This is not a USPTO supplied RCE SB30 form.

Information:

4	Information Disclosure Statement (IDS) Filed (SB/08)	IDS_08.pdf	283473 80f54980f53ce7df775a852dd9463485f87 0905	no	6
---	--	------------	---	----	---

Warnings:

Information:

This is not an USPTO supplied IDS fillable form

5	NPL Documents	ANDERSON_Effects_of_Cyclophosphamide_and_Irradiation.pdf	558130 a3d996525dca2ccb8ad1a22a04e6fd26d17 019d4	no	7
---	---------------	--	--	----	---

Warnings:

Information:

6	NPL Documents	BALINT_Immune_complexes_with_antiglobulin_activity.pdf	540658 f6ba993ac84bf6e5c15681559afe168f6e3c10e9	no	9
Warnings:					
Information:					
7	NPL Documents	BARRETT_Undulations_in_the_Time-Response_Curve.pdf	1750540 9908d3b6e01738cbef031e0370797c993883871	no	7
Warnings:					
Information:					
8	NPL Documents	BORJABAD_eta_Gene_Expression_Profiles_of_HIV-1-Infected.pdf	4646991 c1259549794e9164ca429d9ccfc3cd7209e6427a	no	19
Warnings:					
Information:					
9	NPL Documents	CHAN_eta_Quantitative_Analysis_of_Human_Immunodeficiency_Virus.pdf	4111609 2e5bcd91d14d1615b8434597ea1207005557aecf	no	13
Warnings:					
Information:					
10	NPL Documents	COVENTRY_CRP_identifies_hormostatic immune.pdf	749980 53b8709e3b8c75821290503a4261251b671ea54f	no	8
Warnings:					
Information:					
11	NPL Documents	DENHAM_The_Occurrence_of_Two_Types.pdf	2356487 18226cee55a394e2e913473822098c1ae2cfaf4f	no	17
Warnings:					
Information:					
12	NPL Documents	MING_Studies_on_development_of_treatment_against_retroviruses.pdf	663772 94e757e7258dd9bb349275ca0454674692e8b876	no	4
Warnings:					
Information:					
13	NPL Documents	NORTH_The_Murine_Antitumor.pdf	7430199 f2da9559811cf3d51c48ffbd2466c296e16147	no	67
Warnings:					
Information:					
14	NPL Documents	NORTH_Generation_and_Decay.pdf	1797387 893befa465c1eca643326deae1e70aa47baa7f5	no	17
Warnings:					
Information:					

15	NPL Documents	O'BRIEN_etal_Changes_in_Plasma_HIV-1_RNA.pdf	611812 7dcefe0a9bb2f9945ed2f5d35e13fadd3c2 3545	no	6
----	---------------	--	---	----	---

Warnings:

Information:

16	NPL Documents	QUEVEDO_Possible_Therapeutic_Reversal.pdf	139420 fbff7fad54c77d5b39f83af656f0bc4711fb 9e	no	1
----	---------------	---	--	----	---

Warnings:

Information:

17	NPL Documents	Simpson_Cell-Mediated_Responses.PDF	774516 45ff161aeb28815915a25345596579ee9c72 aded	no	6
----	---------------	-------------------------------------	--	----	---

Warnings:

Information:

18	NPL Documents	CN01817380_OA_referencing_Ming_Meng.pdf	341229 9b2689c2c42130644109d3e8166204add3e 164e6	no	8
----	---------------	---	--	----	---

Warnings:

Information:

19	NPL Documents	AU_Exam_Report_in_2004283322_01Jul2010.pdf	152104 9224369584ff998ce1aba30ba9385d115b5 1e962	no	3
----	---------------	--	--	----	---

Warnings:

Information:

20	NPL Documents	AU_Request_Amend_Spec_in_2004283322_22Jun2010.pdf	1301630 39a175e63b7b7f313ee872b2383c6e216af 77670	no	30
----	---------------	---	---	----	----

Warnings:

Information:

21	NPL Documents	CN_OA_in_2004800389993_24Apr2009_with_English_translation.pdf	492620 19305fa04b165b3e0dfe534ede261527e58 28142	no	9
----	---------------	---	--	----	---

Warnings:

Information:

22	NPL Documents	EP04761461_OA_12-17-2008.pdf	395274 bf72492487445faace6369971da9366fe2f1 4549	no	7
----	---------------	------------------------------	--	----	---

Warnings:

Information:

23	NPL Documents	EP_Comm_Art94_in_04761461_07Aug2009.pdf	392520 b25bdaf53c7bbd2844d7fe5da7c3483ede8 1b105	no	8
----	---------------	---	--	----	---

Warnings:

Information:

24	NPL Documents	EP04761461_OA_08-07-2009.pdf	531473 3636b458316cf9c04f5e436ffa58f3d095b1 153	no	8
----	---------------	------------------------------	---	----	---

Warnings:

Information:

25	NPL Documents	EP04761461_OA_02-24-2010.pdf	923798 f49ee3a533f19948876457bf4ed99ef66b45 6f40	no	15
----	---------------	------------------------------	--	----	----

Warnings:

Information:

26	NPL Documents	EP04761461_OPM_07-02-2010.pdf	1834123 a64d21a567719f9a3f39e1307fb4233bcc5d f3fe	no	29
----	---------------	-------------------------------	---	----	----

Warnings:

Information:

27	NPL Documents	JP2006-535913_OA_10-25-2010.pdf	668552 4c60aab5ddc2a2b76074ae2d633fb897814 36145	no	10
----	---------------	---------------------------------	--	----	----

Warnings:

Information:

28	NPL Documents	MXPAa2006004522_OA_5-18-2009.pdf	272094 198c11ac43d60c236d1fa5b261be05f42e93 5db0	no	4
----	---------------	----------------------------------	--	----	---

Warnings:

Information:

29	NPL Documents	MXPAa2006004522_OA_11-09-2009.pdf	149120 15f497b87bbfc0791646d8e5090da0232f74 da5e	no	2
----	---------------	-----------------------------------	--	----	---

Warnings:

Information:

30	NPL Documents	MXPAa2006004522_OA_03-23-2010.pdf	149347 a6fb4a9a5b37b58e9b9a330878dc4632d52 355fe	no	3
----	---------------	-----------------------------------	--	----	---

Warnings:

Information:

31	NPL Documents	NZ_Exam_Report_in_546873_04Dec2007.pdf	204010 398da2acf86ace45cf3614d325df6315cc8f5 f3c	no	2
----	---------------	--	--	----	---

Warnings:

Information:

32	NPL Documents	NZ_Exam_Report_in_546873_30Sep2009.pdf	136721 5d6a8c92af096d6a2eb7e53038a0ced6ee7f 15a5	no	2
----	---------------	--	--	----	---

Warnings:

Information:

33	Fee Worksheet (PTO-875)	fee-info.pdf	31854 f4fb35a593512ddab69f13581ee0077610f 7ead	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			35519056		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p>New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p>National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p>New International Application Filed with the USPTO as a Receiving Office If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					